Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Concurrent therapy"'
Publikováno v:
Thoracic Cancer, Vol 12, Iss 16, Pp 2233-2240 (2021)
Abstract Background Previous studies have demonstrated the combination of epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) and other antitumor agents may delay drug resistance. In this study, we retrospectively reviewed the
Externí odkaz:
https://doaj.org/article/0d1f79831fe0453e89d5372044c118cb
Autor:
Ryan Miller, Andrew Song, Ayesha Ali, Muneeb Niazi, Voichita Bar-Ad, Nina Martinez, Jon Glass, Iyad Alnahhas, David Andrews, Kevin Judy, James Evans, Christopher Farrell, Maria Werner-Wasik, Inna Chervoneva, Michele Ly, Joshua Palmer, Haisong Liu, Wenyin Shi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionStandard-of-care treatment for patients with newly diagnosed glioblastoma (GBM) after surgery or biopsy includes concurrent chemoradiation followed by maintenance temozolomide (TMZ) with tumor treating fields (TTFields). Preclinical studi
Externí odkaz:
https://doaj.org/article/c807b96170d949a0be737e1861ec0f90
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with objective response rates (ORR) of about 15–25%, and even lower for some cancers. Abnormal vascul
Externí odkaz:
https://doaj.org/article/4199963cc4bf43d2ba1e3398b157889c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vladimír Soška
Publikováno v:
Vnitřní lékařství. 67:37-40
Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a468c27e75397aee4098d10885e24159
https://doi.org/10.36290/vnl.2021.005
https://doi.org/10.36290/vnl.2021.005
Autor:
Maxim Shevtsov, Gabriele Multhoff, Elena Mikhaylova, Atsushi Shibata, Irina Guzhova, Boris Margulis
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 21, p 5284 (2019)
Most molecular chaperones belonging to heat shock protein (HSP) families are known to protect cancer cells from pathologic, environmental and pharmacological stress factors and thereby can hamper anti-cancer therapies. In this review, we present data
Externí odkaz:
https://doaj.org/article/124b3dde97224d2d8c599db1b62f873d
Autor:
Ian J. Butterwick, Jimm Grimm, Sabrina Divekar, Kristin J. Redmond, Lawrence Kleinberg, Irina Kapitanova, Sharmi Biswas, Michel Lacroix, Kenneth M. Forster, Anand Mahadevan, Daniel Garren
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment
Purpose: Tumor treating fields (TTFields) is a novel antimitotic treatment that was first proven effective for glioblastoma multiforme, now with trials for several extracranial indications underway. Several studies focused on concurrent TTFields ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc40ebdaaf0c2341905dd872dd6d1cc
https://doaj.org/article/4862b2224d784d2893d58514bc56e797
https://doaj.org/article/4862b2224d784d2893d58514bc56e797
Autor:
Satoshi Mori
Publikováno v:
Osteoporotic Fracture and Systemic Skeletal Disorders ISBN: 9789811656125
Osteoporotic Fracture and Systemic Skeletal Disorders
Osteoporotic Fracture and Systemic Skeletal Disorders
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9c8c39ea73916a4b1a13088200c53a5
https://doi.org/10.1007/978-981-16-5613-2_28
https://doi.org/10.1007/978-981-16-5613-2_28
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 9, Iss 3, Pp 106-110 (2010)
Warfarin effectiveness and safety is substantially affected by concurrent therapy. This paper reviews the main mechanisms of warfarin interactions with other agents, which underlie adverse effect development: platelet dysfunction, gastro-intestinal e
Externí odkaz:
https://doaj.org/article/3d8f4eaffb914e3dbfbfcff9ee84e8fd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.